Ordering Recommendation

Optimize dose, detect variable pharmocokinetics, and monitor patient adherence.






Tue, Fri


1-5 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation

Prior to testing patient should have had uninterrupted imatinib therapy for at least 29 days with no change in dose or treatment for at least 8 days. Blood draw should be performed immediately prior to the next scheduled dose.


Plasma, Pre-dose (Trough) Draw - At a Steady State Concentration, in K2EDTA (Lavender or Pink) or Lithium Heparin (Green)

Specimen Preparation

Separate from cells within 48 hours of collection. Centrifuge the whole blood for a minimum of 10 minutes to separate the plasma from cells. Carefully draw off the plasma starting from the top of the plasma layer, avoiding the cell layer (contamination of plasma with blood cells may interfere with results). Transfer 1 mL plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature


Unacceptable Conditions

Whole blood, gel separator tubes, light blue (citrate), or yellow top tubes.


Ambient: 7 days; Refrigerated: 30 days; Frozen: 30 days

Reference Interval

500-1999 ng/mL

Interpretive Data

The therapeutic range is based on plasma pre-dose (trough) draw at steady-state concentration. Concentrations above 1000 ng/mL in chronic myelogenous leukemia (CML) patients, and above 1100 ng/mL in gastrointestinal stromal tumor (GIST) patients are statistically associated with an improved response.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)


Hotline History


CPT Codes



Component Test Code* Component Chart Name LOINC
3000540 Imatinib 57844-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • Gleevec
  • Glivac
  • Imatinib Mesylate